Currently in Phase 3 clinical investigation, Retatrutide is one of the most actively researched peptides in metabolic and incretin biology
Our most recent reportwith data through June 2025showed increases in overall anti-obesity medication (AOM) prescribing and AOM tirzepatide and semaglutide compared to March 2025 ( 1 )
Tosin offered a checklist of warning signs that a provider is cutting corners: prescribing compounded GLP-1 products instead of FDA-approved ones, writing a prescription without reviewing your history or ordering labs, having no plan to increase the dose gradually, scheduling no follow-up visits in the first few months, skipping a review of your other medications, ignoring nutrition entirely, never mentioning long-term treatment or what happens if you stop, and tacking on ingredients like vitamin B12 or B6 without a clinical reason
What NOT to use Do not use normal saline (0.9% sodium chloride) as your diluent
Without pharmaceutical regulation, products vary enormously in purity, potency, and safety
19: Sikiric P, Gojkovic S, Krezic I, Smoday IM, Kalogjera L, Zizek H, Oroz K, Vranes H, Vukovic V, Labidi M, Strbe S, Baketic Oreskovic L, Sever M, Tepes M, Knezevic M, Barisic I, Blagaic V, Vlainic J, Dobric I, Staresinic M, Skrtic A, Jurjevic I, Boban Blagaic A, Seiwerth S
)
